Determining the Impact of Opioid Policy on Substance Use and Mental Health-Related Harms: Protocol for a Data Linkage Study.
data linkage
drug policy
general practice
opioid
primary care
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
received:
14
08
2023
accepted:
21
08
2023
revised:
21
08
2023
medline:
17
10
2023
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
epublish
Résumé
Increasing harms related to prescription opioids over the past decade have led to the introduction of a range of key national and state policy initiatives across Australia. These include introducing a mandatory real-time prescription drug-monitoring program in the state of Victoria from April 2020 and a series of changes to subsidies for opioids on the Pharmaceutical Benefit Scheme from June 2020. Together, these changes aim to influence opioid supply and reduce harms related to prescription opioids, yet few studies have specifically explored how these policies have influenced opioid prescribing and related harms in Australia. The aim of this study is to examine the impact of a range of opioid-related policies on hospital admissions and emergency department (ED) presentations in Victoria, Australia. In particular, the study aims to understand the effect of various opioid policies and opioid-prescribing changes on (1) the number and rates of ED presentations and hospital admissions attributed to substance use (ie, opioid and nonopioid related) or mental ill-health (eg, suicide, self-harm, anxiety, and depression), (2) the association between differing opioid dose trajectories and the likelihood of ED presentations and hospital admissions related to substance use and mental ill-health, and (3) whether changes in an individual's opioid prescribing change the risk related to ED presentations and hospital admissions related to substance use and mental ill-health. We will conduct a population-level linked data study. General practice health records obtained from the Population Level Analysis and Reporting platform are linked with person-level data from 3 large hospital networks in Victoria, Australia. Interrupted time series analysis will be used to examine the impact of opioid policies on a range of harms, including the rates of presentations related to substance use (opioid and nonopioid) and mental ill-health among the primary care cohort. Group-based trajectory modeling and a case-crossover design will be used to further explore the impact of changes in opioid dosage and other covariates on opioid and nonopioid poisonings and mental ill-health-related presentations at the patient level. Given that this paper serves as a protocol, there are currently no results available. The deidentified primary health data were sourced from electronic medical records of approximately 4,717,000 patients from 542 consenting general practices over a 6-year period (2017-2022). The submission of results for publication is planned for early 2024. This study will add to the limited evidence base to help understand the impact of opioid policies in Australia, including whether intended or unintended outcomes are occurring as a result. EU PAS Register EUPAS104005; https://www.encepp.eu/encepp/viewResource.htm?id=104006. DERR1-10.2196/51825.
Sections du résumé
BACKGROUND
BACKGROUND
Increasing harms related to prescription opioids over the past decade have led to the introduction of a range of key national and state policy initiatives across Australia. These include introducing a mandatory real-time prescription drug-monitoring program in the state of Victoria from April 2020 and a series of changes to subsidies for opioids on the Pharmaceutical Benefit Scheme from June 2020. Together, these changes aim to influence opioid supply and reduce harms related to prescription opioids, yet few studies have specifically explored how these policies have influenced opioid prescribing and related harms in Australia.
OBJECTIVE
OBJECTIVE
The aim of this study is to examine the impact of a range of opioid-related policies on hospital admissions and emergency department (ED) presentations in Victoria, Australia. In particular, the study aims to understand the effect of various opioid policies and opioid-prescribing changes on (1) the number and rates of ED presentations and hospital admissions attributed to substance use (ie, opioid and nonopioid related) or mental ill-health (eg, suicide, self-harm, anxiety, and depression), (2) the association between differing opioid dose trajectories and the likelihood of ED presentations and hospital admissions related to substance use and mental ill-health, and (3) whether changes in an individual's opioid prescribing change the risk related to ED presentations and hospital admissions related to substance use and mental ill-health.
METHODS
METHODS
We will conduct a population-level linked data study. General practice health records obtained from the Population Level Analysis and Reporting platform are linked with person-level data from 3 large hospital networks in Victoria, Australia. Interrupted time series analysis will be used to examine the impact of opioid policies on a range of harms, including the rates of presentations related to substance use (opioid and nonopioid) and mental ill-health among the primary care cohort. Group-based trajectory modeling and a case-crossover design will be used to further explore the impact of changes in opioid dosage and other covariates on opioid and nonopioid poisonings and mental ill-health-related presentations at the patient level.
RESULTS
RESULTS
Given that this paper serves as a protocol, there are currently no results available. The deidentified primary health data were sourced from electronic medical records of approximately 4,717,000 patients from 542 consenting general practices over a 6-year period (2017-2022). The submission of results for publication is planned for early 2024.
CONCLUSIONS
CONCLUSIONS
This study will add to the limited evidence base to help understand the impact of opioid policies in Australia, including whether intended or unintended outcomes are occurring as a result.
TRIAL REGISTRATION
BACKGROUND
EU PAS Register EUPAS104005; https://www.encepp.eu/encepp/viewResource.htm?id=104006.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/51825.
Identifiants
pubmed: 37847553
pii: v12i1e51825
doi: 10.2196/51825
pmc: PMC10618880
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e51825Informations de copyright
©Ting Xia, Louisa Picco, Samanta Lalic, Rachelle Buchbinder, J Simon Bell, Nadine E Andrew, Dan I Lubman, Christopher Pearce, Suzanne Nielsen. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 17.10.2023.
Références
Med J Aust. 2021 May;214(9):430-432
pubmed: 33885163
Drug Alcohol Depend. 2021 Nov 1;228:109090
pubmed: 34600255
JAMA Netw Open. 2019 Feb 1;2(2):e187621
pubmed: 30707224
Addiction. 2022 Mar;117(3):623-636
pubmed: 34338377
BMJ Open. 2023 Apr 19;13(4):e068059
pubmed: 37076156
Res Social Adm Pharm. 2022 Dec;18(12):4129-4137
pubmed: 35963765
Addiction. 2005 May;100(5):636-42
pubmed: 15847621
Br J Gen Pract. 2023 May 25;73(731):e435-e442
pubmed: 37130611
Drug Alcohol Depend. 2015 Nov 1;156:282-288
pubmed: 26454836
PLoS One. 2020 May 4;15(5):e0232538
pubmed: 32365132
BMJ Open. 2023 May 2;13(5):e067746
pubmed: 37130678
Public Health Res Pract. 2023 Sep 13;33(3):
pubmed: 36792352
BMC Psychiatry. 2020 Jan 31;20(1):40
pubmed: 32005200
BMC Med. 2020 Mar 30;18(1):68
pubmed: 32223746
Drug Alcohol Depend. 2016 May 1;162:79-87
pubmed: 27049582
Aust Prescr. 2018 Feb;41(1):2-3
pubmed: 29507450
EClinicalMedicine. 2022 Jul 18;51:101558
pubmed: 35875817
Pain Med. 2015 Feb;16(2):356-66
pubmed: 25279706
Health Aff (Millwood). 2019 Sep;38(9):1550-1556
pubmed: 31479368
Am J Prev Med. 2019 Dec;57(6):e211-e217
pubmed: 31753274
Pain. 2015 Feb;156(2):231-242
pubmed: 25599444
BMJ Health Care Inform. 2019 Nov;26(1):
pubmed: 31712272
JAMA. 2021 Aug 3;326(5):411-419
pubmed: 34342618
Ann Intern Med. 2017 Aug 01;167(3):181-191
pubmed: 28715848
Pharmacoepidemiol Drug Saf. 2020 Mar;29(3):252-269
pubmed: 31851773
Drug Alcohol Rev. 2020 Feb;39(2):128-134
pubmed: 31841260
J Affect Disord. 2015 Sep 15;184:72-80
pubmed: 26072316
Pain. 2017 Jan;158(1):110-119
pubmed: 27749607
Med J Aust. 2016 Oct 3;205(7):334-5
pubmed: 27681979
J Pain. 2018 Feb;19(2):166-177
pubmed: 29054493
Annu Rev Public Health. 2018 Apr 1;39:5-25
pubmed: 29328873
J Am Board Fam Med. 2019 May-Jun;32(3):362-374
pubmed: 31068400
Lancet Reg Health West Pac. 2021 Jan 29;7:100089
pubmed: 34327417
J Gen Intern Med. 2019 Dec;34(12):2749-2755
pubmed: 31468341
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
BMJ Open. 2018 Apr 13;8(4):e021122
pubmed: 29654048
Health Inf Manag. 2020 Jan;49(1):38-46
pubmed: 31272232
Drug Alcohol Rev. 2019 Mar;38(3):223-225
pubmed: 30860307
Drug Alcohol Depend. 2017 Oct 1;179:291-298
pubmed: 28826104
JAMA. 2019 Nov 19;322(19):1855-1856
pubmed: 31600366
Pain. 2016 Jul;157(7):1489-1498
pubmed: 26963848